Propanc Biopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Propanc Biopharma, Inc. announced a private placement of Series C Preferred Stock and Warrants to Hexstone Capital LLC, approved by majority stockholder consent.
NASDAQ
Propanc Biopharma is set to execute a reverse stock split at a ratio between 1:10,000 and 1:100,000, approved by a majority stockholder, to improve its financing and capital raising ability.